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Objective: Subjects with insomnia have a higher risk of depression, thus possibly making
them live with serious health conditions. To date, information regarding the effect of
Chinese herbal medicines (CHMs), a commonly used complementary and alternative
medicine, on depression risk among people with insomnia is still unknown. This study
aimed to investigate the effect of CHMs on the risk of depression among individuals
with insomnia.
Methods: This cohort study used a national health insurance database to identify 68,573
subjects newly diagnosed with insomnia, aged 20–70 years, who received treatment
between 1998 and 2010. Using propensity score matching, we randomly selected
26,743 CHMs users and 26,743 non-CHMs users from this sample. All enrollees were
followed to the end of 2012 to identify any treatment for depression as the end point.
Cox proportional hazards regression was used to compute the adjusted hazard ratio of
depression associated with CHMs use.
Results: After utilizing the propensity score matching, we randomly selected
26,743 CHMs users and 26,743 non-CHMs users from this sample. During follow
up, 3,328 CHMs users and 6,988 non-CHMs users developed depression at
incidence rates of 17.24 and 37.97 per 1,000 person-years, respectively. CHMs
users had a lower depression risk than the non-CHMs users (adjusted hazard ratio
= 0.44; 95% Confidence Interval, 0.42–0.46). The greatest effect was observed for
those taking CHMs for more than 2 years. Gegen, Huangqin, Dan-Shen, Beimu,
Dahuang, Shegan, Shu-jing-huo-xue-tang, Ge-gen-tang, Shao-yao-gan-cao-tang and
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Píng wèi sǎn were significantly associated with a lower risk of depression.
Conclusions: Findings from this study demonstrated that adding CHMs to conventional
treatment significantly reduces depression risk among patients with insomnia.
Keywords: insomnia, Chinese herbal medicine, depression, complementary and alternative, cohort study

KEY POINTS

(9). Another pharmacological research summarized the
antidepressant mechanisms of active components, such as
elevated synaptic concentrations of monoamines, modifying the
HPA axis dysfunctions, and increasing synaptic plasticity (10).
Such therapeutic benefits bolster the potential of CHMs use for
treating depression in patients with insomnia.
Considering the potential association of insomnia with a
subsequent risk of depression and the limited information
on the capacity of CHMs to modify this association, we
believe findings from a long-term population-based cohort study
may be of importance in allocating medical resources and
instituting evidence-based policymaking. Thus, we examined a
nationwide population-based database to compare the risk of
depression among patients with insomnia who did and did not
receive CHMs.

- This is the first investigation to explore the effects of CHMs use
against the depression onset among individuals with insomnia.
- We discovered that the CHMs use was associated with a
lower risk of depression after adjustment for the potential
confounding factors.
- The more predominant effect was observed among those
receiving CHMs for more than 2 years, with up to 80% lower
risk of depression.
- In addition to the positive effect of CHMs, the findings of
this study further indicated the commonly prescribed herbal
products that may be related to reduced depression risk, thus
paving the way for further pharmacological investigations.

INTRODUCTION

METHODS

Insomnia is a common sleep disorder affecting about one third
of the general population worldwide. It is characterized by
difficulty in falling asleep, difficulty in staying asleep, and sleep
that is non-restorative in nature (1). Compared to the general
population, those with persistent insomnia have a 58% increased
risk of all-cause mortality (2). The rise in incidence of chronic
insomnia not only triggers major health challenges but also
results in tremendous economic loss. The total cost associated
with insomnia is estimated at $92.5–107.5 billion annually in
the US alone (3), which implied that insomnia was clearly an
important public health concern requiring particular attention.
Notably, insomnia would further result in sleepiness, fatigue
or cognitive impairment, thus pre-disposing individuals who
experience insomnia to developing depression. A meta-analysis
of 21 longitudinal studies demonstrated that insomnia may
double the risk of depression independently of conventional risk
factors (4). At its worst, a diagnosis of depression increases the
risk of death by as much as 50% (5). Moved by the tragic case
presented above, interventions geared at preventing or lessening
the susceptibility of depression may be of utmost importance.
In Asian cultures, Chinese herbal medicines (CHMs) are
complementary and alternative medical therapies commonly
used for patients with chronic diseases. Several of these
herbs have been proven to improve cognitive function by
suppressing monoamine oxidase activity and oxidative stress,
upregulating neurotrophins and modulating the function of
the hypothalamic-pituitary-adrenal (HPA) axis in patients with
neurodegenerative diseases (6). Previous research has illustrated
that CHMs produce therapeutic effects of equal magnitude to
hypnosis through multiple bioactivity channels in the central
neural system (7, 8). One systematic review affirmed the efficacy
and safety of CHMs to be as effective as that of antidepressants
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Data Source
The present cohort study analyzed data from the Longitudinal
Health Insurance Database (LHID 2000), which is managed by
the National Health Insurance (NHI) Administration. Taiwan
launched a single-payer NHI program in 1995 to remove
financial barriers to medical care for all legal residents. As of 2017,
over 99% of Taiwan’s population had enrolled in this program.
The LHID 2000 is based on a sub-set of the NHI program made
up of one million randomly sampled people who were traced
retrospectively from 1996 to 2012. These one million insured
individuals did not differ significantly in sex or age from the
general population, as a multistage stratified systematic sampling
method was used (11). This database contains all NHI enrollment
files, claims data and data from a prescription drugs registry,
providing comprehensive utilization information on the subjects
covered by the insurance program.

Ethics
The current investigation used retrospective data from an
administrative database in which patients were made anonymous
to the researchers. It was also conducted in accordance with
the Helsinki Declaration and was approved by the Institutional
Review Board and Ethics Committee of Buddhist Dalin Tzu Chi
Hospital, Taiwan (No. B10004021-3).

Study Participants
The methods used to select the study subjects are illustrated in
Figure 1. Diagnoses in the insurance claims data were coded
using the International Classification of Disease, 9th Revision,
Clinical Modification (ICD-9-CM). Patients who were older than
20 years, and were newly diagnosed with insomnia between 1998
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FIGURE 1 | Flow chart of selection and follow-up of study subjects.

and 2010 (ICD-9-CM codes: 307.41, 307.42, 780.50, 780.52), were
considered for enrollment into the study.
To reduce the potential for disease misclassification, we
selected patients had diagnoses of insomnia in at least three
outpatient visits, or were admitted to the hospital with a primary
diagnosis of insomnia within the observation period (n =
68,573). To establish a temporal link between insomnia and
depression, we excluded those who were followed for <1 year
after the onset of insomnia (n = 1,042) and those who had a
prior diagnosis of depression before the first insomnia diagnosis
(n = 5,319). Patients were identified as having depression if they
had at least three ambulatory visits for treatment or had been
hospitalized due to depression, as reflected in the use of ICD-9CM codes 296.2, 296.3, 300.4, or 311. A group of 62,212 subjects
with insomnia were included in the final data analysis.
As only certified Chinese medicine physicians are permitted
to prescribe CHMs in Taiwan. We, therefore, used the frequency
of visits to Chinese medicine physicians to verify the CHMs
exposure of each insomniac patient. Those receiving CHMs to
treat insomnia for more than 30 days were deemed CHMs users,
whereas those treated for 30 days or less were considered nonCHMs users (12, 13). Based on this procedure, 31,238 cases were
designated as CHMs users. A comparison cohort was randomly
selected from the remaining insured insomnia cases without
CHMs use. For each patient receiving CHMs treatment, one
control without CHMs was selected by 1:1 matching based on
a propensity score. The propensity score was calculated using
logistic regression based on patient demographics and baseline
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comorbidities at enrollment. To consider the immortal time bias
(14), we defined the index date for the follow-up period for the
patients with insomnia who were classified as non-CHMs users
to be the date of the first insomnia diagnosis. The index date for
the follow-up period for the patients with insomnia who used
CHMs was the first date of the initiation of CHMs treatment.
Each patient with insomnia was followed from the index date
until 31 December 2012, death or being censored. The follow-up
time, in person-years (PYs), was calculated for each insomniac
patient until the diagnosis of depression, death or until being
censored due to withdrawal from the insurance system or loss
to follow-up.

Covariates Assessment
Covariates consisted of the baseline sociodemographic
characteristics
and
comorbidities.
Sociodemographic
characteristics considered in this study included age, gender,
income (for estimating insurance payments) and urbanization
level of the registered resident region. Monthly income was
defined as the subject’s own insurable wage and stratified into
three levels: ≤17,880 New Taiwan Dollar (NTD) (low); 17,881–
43,900 NTD (median); and ≥43,901 NTD (high). In addition, we
also grouped the resident region by collapsing each geographic
location into one of three strata, namely, urban (levels 1–2),
suburban (levels 3–4) and rural (levels 5–7), with higher levels
indicating greater urbanization (15). Baseline comorbidities for
each subject were determined by individual medical records in
the year preceding cohort entry, all of which were assessed by
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the established Charlson-Deyo comorbidity index (CCI) (16).
The CCI score consisted of 17 chronic diseases, each with a
score of 1-to-6 points. The sum of these scores was regarded
as a continuous variable for the burden of comorbidities,
with higher scores indicating a more severe impact from the
these comorbidities.

TABLE 1 | Demographic data and selected comorbidities of the study subjects.
Variables

All

Non-CHMs users

CHMs users

n = 26,743(%)

n = 26,743(%)

Age (yr)

0.44

≤50

28,771 (53.8)

14,341 (53.6)

14,430 (54.0)

Statistical Analysis

>50

24,715 (46.2)

12,402 (46.4)

12,313 (46.0)

The SAS version 9.3 software (SAS Institute Inc, Cary, NC, USA)
was used for data analysis. Distributions of socio-demographic
data and comorbidities between the enrollees who did and
did not receive CHMs were compared by the chi-square test
and independent Student’s t-test. Cox proportional hazards
regression analysis was applied to compute the adjusted hazard
ratio (HR) with its 95% confidence interval (CI) of the risk
of depression in association with CHMs use, after accounting
for the confounders reported at baseline. To further test the
robustness of the relationship between CHMs use and depression
risk, we divided the CHMs users into three subgroups: those
using CHMs for 31–365 days, for 366–730 days and for more
than 730 days. The Cox proportional hazards regression analysis
with Bonferroni correction was applied for multiple comparisons
among the groups. We also used the Kaplan-Meier method to
estimate the cumulative risk of depression for different groups
and tested the difference with the log-rank test. Furthermore, a
stratified analysis by age and sex using Cox proportional hazards
regression was conducted to assess the relative risk of depression
associated with CHMs. The proportional hazards assumption
was examined by plotting the log[-log(survival function)] vs. the
log of survival time. Differences of p < 0.05 were determined to
be statistically significant.

Mean (SD)

48.5 ± 12.4

48.5 ± 12.3

48.5 ± 12.5

Gender
17,090 (63.9)

17,134 (64.1)

19,262 (36.0)

9,653 (36.1)

9,609 (35.9)

Low

24,988 (46.7)

12,417 (46.4)

12,571 (47.0)

Median

26,037 (48.7)

13,095 (49.0)

12,942 (48.4)

2,461 (4.6)

1,231 (4.6)

1,230 (4.6)

30,911 (57.8)

15,454 (57.8)

15,457 (57.8)

Monthly income

0.40

Residential area

0.96

Suburban

8,420 (15.7)

4,221 (15.8)

4,199 (15.7)

Rural

14,155 (26.5)

7,068 (26.4)

7,087 (26.5)

4.0 (6.7)

3.9 (6.6)

4.0 (6.8)

CCI
Mean (SD)

0.28

CHMs, Chinese herbal medicines; SD: standard deviation; CCI, Charlson-Deyo
comorbidity index.
∗ All p-values were derived from chi-square test, except for CCI that was calculated with
independent Student’s t-test.

95% CI = 0.18–0.23). Figure 2 presents the Kaplan–Meier
estimates of the cumulative incidence of depression for the
four groups during the 15-year follow-up period, after adjusting
for patients’ age, sex, CCI scores, monthly incomes and
urbanization levels. The cumulative incidence of depression of
those receiving CHMs treatments for more than 730 days was
significantly lower than for those not receiving CHMs (log-rank
test, p < 0.001).
We performed an additional stratified analysis by age
and sex to determine the effect of CHMs on risk of
depression (Table 3). Findings showed that both female
and male patients with insomnia, who also received
CHMs, had a lower risk of depression than did their
non-CHMs counterparts, with an adjusted HR of 0.41
(95% CI = 0.38–0.43) and 0.53 (95% CI = 0.49–0.57),
respectively. A more remarkable beneficial effect of CHMs
was observed among younger subjects. In females, decreases
in adjusted HR were greater for CHMs users ≤50 years of
age (adjusted HR = 0.32, 95% CI = 0.31–0.35); in males,
the effect of CHMs on the risk of depression was greater
for those ≤50 years of age, with an adjusted HR of 0.45
(95% CI = 0.41–0.50).
The most commonly prescribed Chinese herbal products for
insomnia patients are summarized in Table 4. Of these, 10 were
found to substantially lessen the subsequent risk of depression:
Ge Gen (Pueraria lobate), Huang Qin (Scutellaria Baicale), Dan
Shen (Salvia miltiorrhiza), Bei Mu (Fritillariae Thunbergii), Da
Huang (Rheum palmatum), She Gan (Belamcanda chinensis),

RESULTS
The CHMs user and non-CHMs user cohorts each provided data
for 26,743 patients. Table 1 shows the pertinent characteristics of
the two groups, including the distribution of age, sex, monthly
income, residential area and comorbidities, and indicating that
the two groups were comparable on these characteristics. The
mean age of the CHMs users and non-CHMs users was 48.5
± 12.3 and 48.5 ± 12.5 years, respectively. Female patients
predominated in both groups, at 64.0%. The majority of
participants had monthly income levels of 17,881–43,900 NTD
(48.7%) and resided in more urbanized areas (57.8%).
Among the 53,486 patients with insomnia and no history
of prior depression, who were enrolled in this study, 10,316
first episodes of depression were identified; 6,988 were reported
among the non-CHMs users and 3,328 among the CHMs
users during follow-up periods of 184,029.27 and 193,037.73
PYs, respectively. The incidence rate of depression was lower
among CHMs users than in non-CHMs users (17.24 vs.
37.97, respectively, per 1000 PYs), with the adjusted HR of
0.44 (95% CI = 0.42–0.46) (Table 2). Table 2 also lists the
crude and adjusted HRs with Bonferroni correction using
the non-CHMs users as reference. Those who used CHMs
treatment for more than 730 days had an 80% lower risk
of depression than non-CHMs users (adjusted HR = 0.20;

Frontiers in Neurology | www.frontiersin.org

34,224 (64.0)

Male

Urban

0.97
0.69

Female

High

p-value∗
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TABLE 2 | Risk of depression for insomnia subjects with and without CHMs.
Patient group

Event

PYs

Incidence (per 1000 PYs)

Crude HR (95% CI)

Adjusted HR* (95% CI)

Non-CHMs users

6,988

184029.27

37.97

1

1

CHMs users

3,328

193037.73

17.24

0.45 (0.43–0.47)

0.44 (0.42–0.46)

CHMs use within 30–180 days

2,352

107147.47

21.95

0.58 (0.53–0.60)

0.55 (0.53–0.58)

CHMs use within 181–365 days

527

38744.11

13.60

0.36 (0.33–0.39)

0.34 (0.31–0.37)

CHMs use within 366 to 730 days

311

28278.19

11.00

0.29 (0.26–0.33)

0.28 (0.25–0.31)

CHMs use for more than 730 days

138

18867.96

7.31

0.20 (0.17–0.23)

0.20 (0.18–0.23)

*Model adjusted for age, gender, urbanization level, monthly income, medication usage and CCI score.

FIGURE 2 | Cumulative incidence of depression in insomnia patients with and without receiving CHMs treatment during the 15-year study period (Log-rank test,
P < 0.001).

TABLE 3 | Incidence (per 1000 PYs) and depression risk for insomnia patients with and without CHMs in the stratification of sex and age.
Variables

Non-CHMs users

CHMs users

Case

PYs

Incidence

Case

PYs

Incidence

Crude HR (95% CI)

Adjusted HR (95% CI)

0.32 (0.31–0.35)∗

Female
≤50

2,949

52986.41

55.66

1,158

64092.24

18.07

0.32 (0.30–0.35)

>50

2,026

60012.79

33.76

1,106

59922.36

18.46

0.55 (0.49–0.57)

0.53 (0.50–0.57)∗

All

4,975

112999.2

44.03

2,264

124014.6

18.26

0.41 (0.42–0.46)

0.41 (0.38–0.43)

≤50

1,296

39882.51

32.50

590

39102.37

15.09

0.46 (0.41–0.50)

0.45 (0.41–0.50)∗

>50

717

31207.56

22.98

474

29920.76

15.84

0.69 (0.59–0.75)

0.66 (0.59–0.74)∗

2,013

71090.07

28.32

1,064

69023.13

15.42

0.54 (0.49–0.57)

0.53 (0.49–0.57)

Male

All
∗ Model

adjusted for urbanization level, monthly income, medication usage and CCI score.
adjusted for age, urbanization level, monthly income, medication usage and CCI score.

Ω Model

Frontiers in Neurology | www.frontiersin.org
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TABLE 4 | Risk of depression in relation to the 10 most-used single-herb and multi-herb products for insomnia patients.
Chinese herbal name

Number of prescriptions

Crude HR (95% CI)

Adjusted HR * (95% CI)

Yan-Hu-Suo

11,868

0.81 (0.68–1.09)

0.84 (0.69–1.11)

Gegen

11,549

0.46 (0.43–0.49)

0.44 (0.42–0.46)

Huangqin

10,291

0.46 (0.44–0.49)

0.44 (0.42–0.47)

Multiflora

9,803

0.86 (0.72–1.10)

0.88 (0.73–1.09)

Dan-Shen

9,234

0.47 (0.44–0.46)

0.46 (0.43–0.49)

Beimu

9,116

0.43 (0.41–0.46)

0.42 (0.39–0.45)

Dahuang

6,748

0.49 (0.45–0.52)

0.45 (0.42–0.48)

Suan Zao Ren

6,379

0.87 (0.73–1.06)

0.85 (0.73–1.11)

Hai Piao Xiao

6,051

0.85 (0.64–1.08)

0.84 (0.63–1.09)

Shegan

4,527

0.44 (0.40–0.48)

0.42 (0.38–0.46)

Jia-Wei-Xiao-Yao-San

14,573

0.89 (0.73–1.09)

0.88 (0.74–1.05)

Shu-Jing-Huo-Xue-Tang

12,684

0.45 (0.42–0.47)

0.45 (0.42–0.48)

Ge-Gen-Tang

11,549

0.46 (0.43–0.49)

0.45 (0.42–0.48)

Shao-Yao-Gan-Cao-Tang

11,212

0.43 (0.41–0.46)

0.43 (0.40–0.45)

Chuan Xiong Cha Tiao San

9,162

0.87 (0.75–1.07)

0.85 (0.72–1.06)

Single-herb products

Multi-herb products

Píng wèi sǎn

7,931

0.46 (0.43–0.49)

0.45 (0.42–0.47)

Suan Zao Ren Tang

7,883

0.86 (0.72–1.08)

0.89 (0.74–1.07)

Tian Wang Bu Xin Dan

7,706

0.88 (0.74–1.07)

0.89 (0.74–1.10)

Ban Xia Xie Xin Tang

7,566

0.89 (0.76–1.08)

0.88 (0.74–1.11)

Xiao Chai Hu Tang

6,752

0.89 (0.78–1.13)

0.89 (0.76–1.14)

*Model adjusted for age, sex, urbanization level, monthly income, and comorbidities.

colleagues discovered that SJHXT could modulate the activity
of the alpha-2 adrenoceptor (α2-AR) (21). A subsequent study
indicated that depressive disorders appeared to be associated
with increased α2AR sensitivity and responsiveness (22). The
dysregulation of the α2-AR pathway may contribute to the release
of pro-inflammatory cytokines, such as tumor necrosis factorα (TNF-α), interleukin-1 (IL-1) and IL-6, thus increasing the
susceptibility to depression (23).
The current study indicated that the use of SYGCT could
lessen the risk of depression for those with insomnia. We
speculate that the conspicuous anti-depressant effect of SYGCT
may be related to its ingredients, including Paeonia lactiflora
Pall. and Glycyrrhiza uralensis. A recent study showed that P.
lactiflora Pall., a major compound purified from this formula,
can significantly inhibit the hyperfunction of the HPA axis
(24). Meanwhile, G. uralensis works by promoting the release
of 5-hydroxytryptamine and increasing synaptic plasticity in
the hippocampus (10), thereby allowing neurotransmitters to
function more efficiently.
Another herbal product proven effective in lessening
depression risk is PWS. An earlier report suggests that
Magnolia officinalis, a major component in PWS, can inhibit
neuroinflammation and oxidative stress in the prefrontal
cortex and improve the levels of brain-derived neurotrophic
factor (BDNF) protein in the hippocampus, as shown in a
rodent model of depressive disorder (25). We also identified
the positive therapeutic effects of GGT, as well as of Ge Gen.

Shu-jing-huo-xue-tang (SJHXT), Ge-gen-tang (GGT), Shao-yaogan-cao-tang (SYGCT) and Ping-wei–san (PWS).

DISCUSSION
This is the first large scale, retrospective cohort study exploring
the risk of depression in patients with insomnia who either
received or did not receive CHMs treatment. Although several
studies were reported on the benefit of using CHMs for sleep
disorders, or for other psychological problems (17–19), no
studies have yet explored the relationship of CHMs with the risk
of depression among those with sleep disorders.
The findings of the present study are consistent with those
of prior epidemiological studies, showing that insomnia usually
occurs before the first instance of depression (20). Our study
lends initial support for integrating CHMs into conventional
therapy, and suggests that such practice may reduce the risk of
depression by as much as 60%. The dose-response relationship
reported herein could further clarify the causality between
CHMs use and a reduced susceptibility to develop depression.
Our results indicate that the extracts of some Chinese herbal
products may suppress the production of inflammatory cytokines
and modulate the neurotransmitter imbalance that results
in depression.
For example, the commonly prescribed multi-herb formula
SJHXT was found to efficiently diminish the risk of depression
in patients with insomnia. Using a rodent model, Shu and
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include these factors would be beneficial in shedding further light
on our findings. Third, although continuous use of CHMs in our
study indicated a significant benefit, well-designed randomized
controlled trials are still needed to confirm the effect of specific
medicines. These limitations notwithstanding, this study also
had considerable advantages. The database used in this study is
representative of the entire Taiwanese population, and the large
sample size ensured reliable findings. In addition, the use of a
longitudinal cohort study design allowed the robust examination
of the causal relationship between high intensity CHMs use and
lower risk of depression in people with insomnia.

We speculate that puerarin, a major isoflavone glycoside
purified from these agents, may increase cerebral blood flow
via multiple neuroprotective effects, including anti-apoptosis
and anti-inflammatory effects, and reduce oxidative stress (26),
which may point to the possible mechanisms responsible for the
positive effects of these formulae.
With respect to other commonly used single-herb products,
we observed that the use of Dan-Shen was related to a reduced
risk of depression onset. This remedy has been shown to protect
mice from Aβ-induced neurotoxicity by inhibiting increases in
TNF-α, IL-6 or TNF-α levels (27, 28). These mediators are
well-known to play important roles in the pathogenesis of
neuropsychiatric symptoms, especially depression (29).
Additionally, Huang-Qin, Da-Huang, Bei-Mu and She-Gan
are believed to exert their neuroprotection effect by suppressing
pivotal activities of nuclear factor kappa-light-chain-enhancer
of activated B cells associated with inflammatory pathways and
cell apoptosis (30–34). Furthermore, the baicalin in HuangQin and emodin in Da-Huang can mediate BDNF expression,
ameliorating depressive-like behavior (35, 36). BDNF in brain
areas related to emotions, such as the hippocampus and cortex,
can support the survival of neurons, as well as the differentiation
and growth of new synapses (37, 38). Finally, it has been
argued that tectorigenin, an isoflavonoid found in She-Gan,
has a confirmed neuroprotective effect against cytotoxicity and
apoptosis (39, 40).
Findings regarding the positive therapeutic effect of herbal
formulas observed in this study, however, were not compatible
with the findings from an earlier report (41). It could be
speculated that these conflicting findings are partially due to
the differences in the classifications of exposure of interest. For
example, in the study of Chen and colleagues, enrollees were
recruited with a single diagnostic code for insomnia, which
differed from the approach we adopted. Priori study had pointed
out while using the administration database, the algorithm
requiring at least 3 outpatient service claims, or at least 1
inpatient hospitalization claim during the study period (42). The
adopted procedure greatly strengthened the diagnostic validity
and minimized possible potential misclassifications of our study.
While our study is the first to investigate the relation
between CHMs use and depression risk among patients with
insomnia, there are several important limitations. First, when
using secondary health care databases, there is always the risk of
errors in the coding process. To minimize this bias, we enrolled
only persons with new-onset insomnia or depression, and only
after the patients had at least three outpatient visits reporting a
consistent diagnoses or at least one such inpatient admission. It
should also be noted that the NHI of Taiwan randomly reviews
the charts and audits medical charges to verify the accuracy
of claims. However, the coding approach and data availability
were similar between the two groups, and any misclassification
bias would have likely been non-differential and toward the null
hypothesis, thus, if anything, resulting in an underestimation of
the observed effect. Second, the LHID lacks information on social
network relationships, family history, personality attributes,
laboratory data and education level. Thus, future studies that
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CONCLUSION
This is the first large population-based investigation to delineate
the impact of CHMs on the risk of depression among patients
with insomnia. The findings could serve as references for further
studies concerning the influence of CHMs on other medical
complications resulting from insomnia. We found that the
integration of CHMs into conventional therapy reduced the
subsequent risk of depression by 56%, with greater benefits
in those receiving CHMs for longer than 2 years. Healthcare
providers may consider integrating CHMs into therapeutic
care to ameliorate the clinical manifestations of insomnia in
their patients.
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